retatrutide clinical trial results obesity Phase 3: 28.7% Weight Loss (2026) Retatrutide Clinical Trial Results Reviewed

An invention was submitted for a patent on 12 November 1996 [7], and the scientific article was submitted for publication in the Journal of Clinical Investigation 20 June 1997 and published 1st February 1998 [6]

GLP-1 is short for glucagon-like peptide-1 agonist

Unsupervised Cosmetic Use (CRITICAL WARNING): Its use as an unsupervised cosmetic tanning agent is highly discouraged by health authorities (FDA, TGA, HPRA) due to the unknown long-term risk of melanocytic proliferation and the development of new or atypical moles

By binding to GLP-1 receptors in the brain, these medications promote feelings of fullness (satiety), reduce appetite, and aid in weight loss